The weak EPS won’t be praised by investors imo. Recell Go won’t be a catalyst until it gets that FDA stamp of approval. New data for FDA doesn’t ensure victory; approval does. But the company still needs to execute to obtain profitability by some time in 2025. —Still paying back a high SOFR-rate loan in the meantime.
The weak EPS won’t be praised by investors imo. Recell Go won’t...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.96 |
Change
0.180(6.47%) |
Mkt cap ! $184.0M | |||
| Open | High | Low | Value | Volume |
| $2.88 | $3.02 | $2.85 | $1.215M | 413.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2499 | $2.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.98 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.98 |
Change
0.180 ( 8.35 %) |
||||
| Open | High | Low | Volume | ||
| $2.88 | $3.01 | $2.88 | 6348 | ||
| Last updated 15.51pm 08/05/2024 ? | |||||
| AVH (ASX) Chart |